Scrip

Staying on top of the rapidly changing biopharmaceutical industry is crucial for your success. However, it can be quite challenging. That’s where Scrip comes in. Whether you need information on licensing, clinical trials, or competitor movements, Scrip covers it all. From small biotech startups to large multinational companies, and across regions like the US, Europe, Asia Pacific, and Latin America, Scrip ensures you're informed about the important developments that can keep you ahead of your competitors.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

N/A

Country

N/A

Articles

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances

Feb 13, 2024 | scrip.pharmaintelligence.informa.com | Eleanor Malone

Analysis Executive Summary More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends

Feb 4, 2024 | scrip.pharmaintelligence.informa.com | Eleanor Malone

Analysis Executive Summary Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes. You may also be interested in... Existing Subscriber? Sign in to continue reading. New to Scrip? Start a free trial today!
Weighty Matters: The Obesity Market Now… And In Years To Come

Jan 26, 2024 | scrip.pharmaintelligence.informa.com | Elizabeth Cairns |Kosh Naran

Data Executive Summary INFOGRAPHIC: This overview of the obesity market shows the biggest money-spinners in terms of products and mechanisms, the biggest investors and dealmakers – and looks at how some of the notable current and potential future therapies stack up in the clinic. You may also be interested in... Existing Subscriber? Sign in to continue reading. New to Scrip? Start a free trial today!
Scrip Asks...What Does 2024 Hold For Biopharma? Part 2: The Funding Environment, M&A And Partnering

Jan 16, 2024 | scrip.pharmaintelligence.informa.com | Eleanor Malone

Analysis Executive Summary Biotech entrepreneurs tend to be an optimistic group, and there were many pockets of hope for 2024. However, the consensus remains that depressed valuations and paucity of fresh funds will continue to pose a challenge for the sector, and companies will need to prioritize carefully and work even harder to demonstrate and create value.
Corporate VCs Play A Bigger Role In Hard Times

Nov 30, 2023 | scrip.pharmaintelligence.informa.com | Elizabeth Cairns |Edwin Elmhirst

Analysis Executive Summary The investment wings of big biopharma are taking part in a larger proportion of VC deals than ever before. You may also be interested in... Existing Subscriber? Sign in to continue reading. New to Scrip? Start a free trial today!
Lilly’s Zepbound: The Biggest-Selling Drug In The World, Ever?

Nov 15, 2023 | scrip.pharmaintelligence.informa.com | Elizabeth Cairns |Edwin Elmhirst

Data Executive Summary Humira currently holds the record as the bestselling drug ever. But Keytruda is coming for its crown – and beyond that, Zepbound. You may also be interested in... Existing Subscriber? Sign in to continue reading. New to Scrip? Start a free trial today!
Bristol’s New Launches Hit Reality As New Product Portfolio Forecast Is Revised

Oct 26, 2023 | scrip.pharmaintelligence.informa.com | Mary Jo Laffler

News Executive Summary With slower than expected sales of some newer products, Bristol lowered mid-term guidance for its new product portfolio and extended the timeline for reaching the goal to 2026. You may also be interested in... Existing Subscriber? Sign in to continue reading. New to Scrip? Start a free trial today!
It’s Official: The Merck-Daiichi Deal Has The Biggest Upfront Ever

Oct 23, 2023 | scrip.pharmaintelligence.informa.com | Elizabeth Cairns |Edwin Elmhirst

Data Executive Summary But the partners will have to avoid the pitfalls that have bedevilled several other expensive licensing deals. You may also be interested in... Existing Subscriber? Sign in to continue reading. New to Scrip? Start a free trial today!
Infographic: A Snapshot Of Non-Alcoholic Steatohepatitis R&D

Sep 15, 2023 | scrip.pharmaintelligence.informa.com | Joseph Haas |Nancy Pham

Data Executive Summary After a multi-year lull, NASH R&D has picked up this past year with key data readouts, several programs advancing toward Phase III and Madrigal's resmetirom under FDA review with a March 2024 action. This graphic provides a look at the overall status of NASH drug R&D. You may also be interested in... Existing Subscriber? Sign in to continue reading. New to Scrip? Start a free trial today!
Hua Medicine's Chen On Product Launch, Bayer Partnership And Reimbursement

Sep 4, 2023 | scrip.pharmaintelligence.informa.com | Brian Yang

Interviews Executive Summary Within a month of obtaining its global first approval in China, Hua Medicine's dorzagliatin is already available in hospitals. What was behind the successful launch of the first-in-class diabetes agent, what are reimbursement plans and how will local commercialization partner Bayer help? Founder and CEO Li Chen sits down to discuss these and other strategies. Source: Shutterstock Hua Medicine (Shanghai) Ltd.